Open AccessNivolumab and immune‐mediated colitis
Author(s) -
Walker Heather,
Brennan Paul,
Groome Maximillian,
Walsh Shaun,
Carey Frank
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2027
Subject(s) - medicine , nivolumab , discontinuation , colitis , methylprednisolone , adverse effect , immune system , intensive care medicine , immunology , immunotherapy
Key Clinical Message Nivolumab is associated with a number of immune‐regulated adverse events, including immune‐mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.